The histone deacetylase SIRT2 stabilizes Myc oncoproteins

Cell Death and Differentiation

Volumn 20, Issue 3, 2013, Pages 503-514

  Liu, P Y ^a   Xu, N ^a   Malyukova, A ^a   Scarlett, C J ^b,c   Sun, Y T ^a   Zhang, X D ^d   Ling, D ^a   Su, S P ^a   Nelson, C ^a   Chang, D K ^b,e,f   Koach, J ^a   Tee, A E ^a   Haber, M ^a   Norris, M D ^a   Toon, C ^b   Rooman, I ^b   Xue, C ^a   Cheung, B B ^a   Kumar, S ^g   Marshall, G M ^a,h   Biankin, A V ^b,e,f   Liu, T ^a,f   more..

^a University of New South Wales   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g CENTRE FOR CANCER BIOLOGY   (Australia)

^h SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

histone deacetylase; N Myc; NEDD4; neuroblastoma; pancreatic cancer; SIRT2

Indexed keywords

AURORA A KINASE; MYC PROTEIN; SIRTUIN 2; UBIQUITIN PROTEIN LIGASE NEDD4;

ARTICLE; CANCER CELL; CELL PROLIFERATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTONE UBIQUITINATION; NEUROBLASTOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; UPREGULATION;

CELL LINE, TUMOR; CELL PROLIFERATION; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; GENE EXPRESSION; HUMANS; NAPHTHOLS; PHENYLPROPIONATES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STABILITY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MYC; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SIRTUIN 2; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION; UP-REGULATION;

EID: 84873736861     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2012.147     Document Type: Article

References (47)

1. Gustafson WC, Weiss WA. Myc proteins as therapeutic targets. Oncogene 2010; 29: 1249-1259.
2. Brodeur GM. Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-216.
3. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999; 17: 2264-2279.
4. Mahlamaki EH, Barlund M, Tanner M, Gorunova L, Hoglund M, Karhu R et al. Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. Genes Chromosomes Cancer 2002; 35: 353-358.
5. Schleger C, Verbeke C, Hildenbrand R, Zentgraf H, Bleyl U. C-myc activation in primary and metastatic ductal adenocarcinoma of the pancreas: Incidence, mechanisms, and clinical significance. Mod Pathol 2002; 15: 462-469.
6. Marshall GM, Gherardi S, Xu N, Neiron Z, Trahair T, Scarlett CJ et al. Transcriptional upregulation of histone deacetylase 2 promotes myc-induced oncogenic effects. Oncogene 2010; 29: 5957-5968.
7. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple ras-dependent phosphorylation pathways regulate myc protein stability. Genes Dev 2000; 14: 2501-2514.
8. Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N et al. Stabilization of n-myc is a critical function of aurora a in human neuroblastoma. Cancer Cell 2009; 15: 67-78.
9. Amati B. Myc degradation: Dancing with ubiquitin ligases. Proc Natl Acad Sci USA 2004; 101: 8843-8844.
10. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J et al. Genomic targets of the human c-myc protein. Genes Dev 2003; 17: 1115-1129.
11. Patel JH, Loboda AP, Showe MK, Showe LC, McMahon SB. Analysis of genomic targets reveals complex functions of myc. Nat Rev Cancer 2004; 4: 562-568.
12. Pelengaris S, Khan M, Evan G. C-myc: More than just a matter of life and death. Nat Rev Cancer 2002; 2: 764-776.
13. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev 2008; 22: 2755-2766.
14. van Riggelen J, Yetil A, Felsher DW. Myc as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer 2010; 10: 301-309.
15. Cole MD, Cowling VH. Transcription-independent functions of myc: Regulation of translation and DNA replication. Nat Rev Mol Cell Biol 2008; 9: 810-815.
16. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 2001; 1: 194-202.
17. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G et al. Loss of acetylation at lys16 and trimethylation at lys20 of histone h4 is a common hallmark of human cancer. Nat Genet 2005; 37: 391-400.
18. Vaquero A, Scher MB, Lee DH, Sutton A, Cheng HL, Alt FW et al. Sirt2 is a histone deacetylase with preference for histone h4 lys 16 during mitosis. Genes Dev 2006; 20: 1256-1261.
19. Rotili D, Carafa V, Tarantino D, Botta G, Nebbioso A, Altucci L et al. Simplification of the tetracyclic sirt1-selective inhibitor mc2141: Coumarin- and pyrimidinebased sirt1/2 inhibitors with different selectivity profile. Bioorg Med Chem 2011; 19: 3659-3668.
20. Zhang Y, Au Q, Zhang M, Barber JR, Ng SC, Zhang B. Identification of a small molecule sirt2 inhibitor with selective tumor cytotoxicity. Biochem Biophys Res Commun 2009; 386: 729-733.
21. Lara E, Mai A, Calvanese V, Altucci L, Lopez-Nieva P, Martinez-Chantar ML et al. Salermide, a sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 2009; 28: 781-791.
22. Marshall GM, Liu PY, Gherardi S, Scarlett CJ, Bedalov A, Xu N et al. Sirt1 promotes n-myc oncogenesis through a positive feedback loop involving the effects of mkp3 and erk on n-myc protein stability. PLoS Genet 2011; 7: e1002135.
23. Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem 2003; 278: 51606-51612.
24. Liu T, Tee AE, Porro A, Smith SA, Dwarte T, Liu PY et al. Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for myc oncogenesis. Proc Natl Acad Sci USA 2007; 104: 18682-18687.
25. Yang B, Kumar S. Nedd4 and nedd4-2: Closely related ubiquitin-protein ligases with distinct physiological functions. Cell Death Differ 2010; 17: 68-77.
26. Rotin D, Kumar S. Physiological functions of the hect family of ubiquitin ligases. Nat Rev Mol Cell Biol 2009; 10: 398-409.
27. Harvey KF, Shearwin-Whyatt LM, Fotia A, Parton RG, Kumar S. N4wbp5, a potential target for ubiquitination by the nedd4 family of proteins, is a novel golgi-associated protein. J Biol Chem 2002; 277: 9307-9317.
28. Hamilton MH, Tcherepanova I, Huibregtse JM, McDonnell DP. Nuclear import/export of hrpf1/nedd4 regulates the ubiquitin-dependent degradation of its nuclear substrates. J Biol Chem 2001; 276: 26324-26331.
29. Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X et al. Sirt2 maintains genome integrity and suppresses tumorigenesis through regulating apc/c activity. Cancer Cell 2011; 20: 487-499.
30. Li Y, Matsumori H, Nakayama Y, Osaki M, Kojima H, Kurimasa A et al. Sirt2 downregulation in hela can induce p53 accumulation via p38 mapk activation-dependent p300 decrease, eventually leading to apoptosis. Genes Cells 2011; 16: 34-45.
31. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN et al. The fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation- dependent c-myc protein degradation. Proc Natl Acad Sci USA 2004; 101: 9085-9090.
32. Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP. Skp2 regulates myc protein stability and activity. Mol Cell 2003; 11: 1177-1188.
33. von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C et al. The f-box protein skp2 participates in c-myc proteosomal degradation and acts as a cofactor for c-myc-regulated transcription. Mol Cell 2003; 11: 1189-1200.
34. Zhao X, Heng JI, Guardavaccaro D, Jiang R, Pagano M, Guillemot F et al. The hectdomain ubiquitin ligase huwe1 controls neural differentiation and proliferation by destabilizing the n-myc oncoprotein. Nat Cell Biol 2008; 10: 643-653.
35. Inoue T, Hiratsuka M, Osaki M, Yamada H, Kishimoto I, Yamaguchi S et al. Sirt2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene 2007; 26: 945-957.
36. He X, Nie H, Hong Y, Sheng C, XiaW, Ying W. Sirt2 activity is required for the survival of c6 glioma cells. Biochem Biophys Res Commun 2012; 417: 468-472.
37. Dan L, Klimenkova O, Klimiankou M, Klusmann JH, van den Heuvel-Eibrink MM, Reinhardt D et al. The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica 2012; 97: 551-519.
38. Matsushita N, Takami Y, Kimura M, Tachiiri S, Ishiai M, Nakayama T et al. Role of naddependent deacetylases sirt1 and sirt2 in radiation and cisplatin-induced cell death in vertebrate cells. Genes Cells 2005; 10: 321-332.
39. Zhao Y, Yang J, Liao W, Liu X, Zhang H, Wang S et al. Cytosolic foxo1 is essential for the induction of autophagy and tumour suppressor activity. Nat Cell Biol 2011; 12: 665-675.
40. Kim WJ, Lee JW, Quan C, Youn HJ, Kim HM, Bae SC. Nicotinamide inhibits growth of carcinogen induced mouse bladder tumor and human bladder tumor xenograft through upregulation of runx3 and p300. J Urol 2011; 185: 2366-2375.
41. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25: 84-90.
42. Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, Goehle S et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 2006; 66: 4368-4377.
43. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008; 13: 454-463.
44. Li L, Wang L, Wang Z, Ho Y, McDonald T, Holyoake TL et al. Activation of p53 by sirt1 inhibition enhances elimination of cml leukemia stem cells in combination with imatinib. Cancer Cell 2012; 21: 266-281.
45. Yuan H, Wang Z, Li L, Zhang H, Modi H, Horne D et al. Activation of stress response gene sirt1 by bcr-abl promotes leukemogenesis. Blood 2012; 119: 1904-1914.
46. Tee AE, Marshall GM, Liu PY, Xu N, Haber M, Norris MD et al. Opposing effects of two tissue transglutaminase protein isoforms in neuroblastoma cell differentiation. J Biol Chem 2010; 285: 3561-3567.
47. Liu T, Liu PY, Tee AE, Haber M, Norris MD, Gleave ME et al. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. Eur J Cancer 2009; 45: 1846-1854.